Novel targeted therapies and combinations for the treatment of multiple Myeloma

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 13, Issue 1, 2013, Pages 2-15

  Agarwal, Amit ^a   Mahadevan, Daruka ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

HDAC inhibitors; IMiDs; Monoclonal antibodies; mTOR inhibitors; Multiple myeloma; Proteasome inhibitors; Targeted therapy

Indexed keywords

3 METHYLADENINE; BORTEZOMIB; CARFILZOMIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DACETUZUMAB; DARATUMUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; INTERLEUKIN 6; IXAZOMIB CITRATE; LENALIDOMIDE; LUCATUMUMAB; MELPHALAN; MILATUZUMAB; PANOBINOSTAT; PERIFOSINE; PLACEBO; POMALIDOMIDE; SALINOSPORAMIDE A; SILTUXIMAB; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; TOCILIZUMAB; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ANEMIA; APOPTOSIS; AUTOPHAGY; CANCER CELL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; HUMAN; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OSTEOCLAST; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; REVIEW; STOMATITIS; THROMBOCYTOPENIA; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR GENE; UNFOLDED PROTEIN RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; PROTEASOME INHIBITORS; TOR SERINE-THREONINE KINASES;

EID: 84876733126     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X11313010002     Document Type: Review

References (113)

1. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Database. Available from: http://seer.cancer.gov/.
2. Anderson, K.C.; Carrasco R.D. Pathogenesis of myeloma. Annu. Rev. Pathol., 2011, 6, p. 249-274.
3. Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P.G., Anderson, K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer, 2007, 7(8), 585-598.
4. Adams, J. The proteasome: a suitable antineoplastic target. Nat Rev. Cancer, 2004, 4(5), 349-360.
5. Jeremias, I., Kupatt, C.; Baumann, B.; Herr, I.; Wirth, T.; Debatin, K.M. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood, 1998, 91(12), 4624-4631.
6. Hideshima, T., Ikeda, H.; Chauhan, D.; Okawa, Y.; Raje, N.; Podar, K.; Mitsiades, C.; Munshi, N.C., Richardson, P.G.; Carrasco, R.D.; Anderson, KC. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood, 2009, 114(5), 1046-1052.
7. Conticello, C., Giuffrida, R.; Adamo, L.; Anastasi, G.; Martinetti, D.; Salomone, E.; Colarossi, C.; Amato, G.; Gorgone, A.; Romano, A.; Iannolo, G.; De Maria, R.; Giustolisi, R.; Gulisano, M.; Di Raimondo, F. F-kappa. B localization in multiple myeloma plasma cells and mesenchymal cells. Leuk. Res., 2011, 35(1), 52-60.
8. Mitsiades, N., Mitsiades, C.S., Poulaki, V.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T.A.; Treon, S.P.; Munshi, N.C.; Richardson, P.G.; Hideshima, T.; Anderson, K.C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA, 2002, 99(22), 14374-14379.
9. Podar, K., Shringarpure, R.; Tai, Y.T.; Simoncini, M.; Sattler, M.; Ishitsuka, K.; Richardson, P.G.; Hideshima, T.; Chauhan, D.; Anderson, K.C. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res., 2004, 64(20): 7500-7506.
10. Richardson, P.G., Barlogie, B.; Berenson, J.; Singhal, S.; Jagannath, S.; Irwin, D.; Rajkumar, S.V.; Srkalovic, G.; Alsina, M.; Alexanian, R.; Siegel, D.; Orlowski, R.Z.; Kuter, D.; Limentani, S.A.; Lee, S.; Hideshima, T.; Esseltine, D.L.; Kauffman, M.; Adams, J.; Schenkein, D.P.; Anderson, K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med., 2003, 348(26), 2609-2617.
11. Jagannath, S.; Barlogie, B.; Berenson, J.R.; Siegel, D.S.; Irwin, D.; Richardson, P.G.; Niesvizky, R.; Alexanian, R.; Limentani, S.A.; Alsina, M.; Esseltine, D.L.; Anderson, K.C. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br. J. Haematol., 2008, 143(4). 537-540.
12. Richardson, P.G., Sonneveld, P.; Schuster, M.W.; Irwin, D.; Stadtmauer, E.A.; Facon, T.; Harousseau, J.L.; Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H.; Reece, D.; San-Miguel, J.F.; Bladé, J.; Boccadoro, M.; Cavenagh, J.; Dalton, W.S.; Boral, A.L.; Esseltine, D.L.; Porter, J.B.; Schenkein, D.; Anderson, K.C.; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med., 2005, 352(24), 2487-2498.
13. Harousseau, J.L., Attal, M.; Avet-Loiseau, H.; Marit, G.; Caillot, D.; Mohty, M.; Lenain, P.; Hulin, C.; Facon, T.; Casassus, P.; Michallet, M.; Maisonneuve, H.; Benboubker, L.; Maloisel, F.; Petillon, M.O.; Webb, I.; Mathiot, C.; Moreau, P.Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J. Clin. Oncol., 2010, 28(30), 4621-4629.
14. Cavo, M. P.F.; Tacchetti, P.; Galli, M.; Perrone, G.; Petrucci, M.T.; et al. Bortezomib (Velcade®)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM) in ASH Annual Meeting. 2007.
15. Mateos, M.V.; Hernández, J.M.; Hernández, M.T.; Gutiérrez, N.C.; Palomera, L.; Fuertes, M.; Díaz-Mediavilla, J.; Lahuerta, J.J.; de la Rubia, J.; Terol, M.J.; Sureda, A.; Bargay, J.; Ribas, P.; de Arriba, F.; Alegre, A.; Oriol, A.; Carrera, D.; García-Laraña, J.; García-Sanz, R.; Bladé, J.; Prósper, F.; Mateo, G.; Esseltine, D.L.; van de Velde, H.; San Miguel, J.F. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood, 2006, 108(7), 2165-2172.
16. Kuhn, D.J.; Chen, Q.; Voorhees, P.M.; Strader, J.S.; Shenk, K.D.; Sun, C.M.; Demo, S.D.; Bennett, M.K.; van Leeuwen, F.W.; Chanan-Khan, A.A.; Orlowski, R.Z. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 2007, 110(9), 3281-3290.
17. Jagannath, S.R.V.; Stewart, K.; Somlo, G.; Jakubowiak, A.; Trudel, R.; Schwartz, D.; Siegel Kunkel, L. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J. Clin Oncol., 2009, 27(15s).
18. Vij, R. M.W.; Orlowski, R.; Stewart, A.K.; Jagannath, S.; Kukreti, V.; Le, M.H.; Kunkel, L.; Siegel, D. PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update. in ASCO Annual Meeting. 2009.
19. Richardson, P.G.; Briemberg, H.; Jagannath, S.; Wen, P.Y.; Barlogie, B.; Berenson, J.; Singhal, S.; Siegel, D.S.; Irwin, D.; Schuster, M.; Srkalovic, G.; Alexanian, R.; Rajkumar, S.V.; Limentani, S.; Alsina, M.; Orlowski, R.Z.; Najarian, K.; Esseltine, D.; Anderson, K.C.; Amato, A.A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol., 2006, 24(19), 3113-3120.
20. Arastu-Kapur, S.; Anderl, J.L.; Kraus, M.; Parlati, F.; Shenk, K.D.; Lee, S.J.; Muchamuel, T.; Bennett, M.K.; Driessen, C.; Ball, A.J.; Kirk, C.J. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res., 2011, 17(9), 2734-2743.
21. Clinical Trials. Gov. Available from: www.clinicaltrials.gov.
22. Chauhan, D.; Catley, L.; Li, G.; Podar, K.; Hideshima, T.; Velankar, M.; Mitsiades, C.; Mitsiades, N.; Yasui, H.; Letai, A.; Ovaa, H.; Berkers, C.; Nicholson, B.; Chao, T.H.; Neuteboom, S.T.; Richardson, P.; Palladino, M.A.; Anderson, K.C. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell, 2005, 8(5), p. 407-419.
23. Piva, R.; Ruggeri, B.; Williams, M.; Costa, G.; Tamagno, I.; Ferrero, D.; Giai, V.; Coscia, M.; Peola, S.; Massaia, M.; Pezzoni, G.; Allievi, C.; Pescalli, N.; Cassin, M.; di Giovine, S.; Nicoli P.; de Feudis, P.; Strepponi, I.; Roato, I.; Ferracini, R.; Bussolati, B.; Camussi, G.; Jones-Bolin, S.; Hunter, K.; Zhao, H.; Neri, A.; Palumbo, A.; Berkers, C.; Ovaa, H.; Bernareggi, A.; Inghirami, G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood, 2008, 111(5), 2765-2775.
24. Chauhan, D.; Singh, A.; Brahmandam, M.; Podar, K.; Hideshima, T.; Richardson, P.; Munshi, N.; Palladino, M.A.; Anderson, K.C. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 2008, 111(3), 1654-1664.
25. Rajkumar, S.V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol., 2011, 86(1), 57-65.
26. Mitsiades, N.; Mitsiades, C.S.; Poulaki, V.; Chauhan, D.; Richardson, P.G.; Hideshima, T.; Munshi, N.C.; Treon, S.P.; Anderson, K.C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99(12), 4525-4530.
27. D'Amato, R.J.; Lentzsch, S.; Anderson, K.C.; Rogers, M.S. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin. Oncol., 2001, 28(6), 597-601.
28. Lacy, M.Q. New Immunomodulatory Drugs in Myeloma. Curr. Hematol. Malig. Rep., 2011.
29. Escoubet-Lozach, L.; Lin, I.L.; Jensen-Pergakes, K.; Brady, H.A.; Gandhi, A.K.; Schafer, P.H.; Muller, G.W.; Worland, P.J.; Chan, K.W.; Verhelle, D. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res., 2009, 69(18), 7347-7356.
30. Corral, L.G.; Haslett, P.A.; Muller, G.W.; Chen, R.; Wong, L.M.; Ocampo, C.J.; Patterson, R.T.; Stirling, D.I.; Kaplan, G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol., 1999, 163(1), 380-386.
31. Haslett, P.A., et al., Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med., 1998. 187(11), 1885-1892.
32. von Lilienfeld-Toal, M.; Hahn-Ast, C.; Furkert, K.; Hoffmann, F.; Naumann, R.; Bargou, R.; Cook, G.; Glasmacher, A. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur. J. Haematol., 2008, 81(4), 247-252.
33. Dimopoulos, M.; Spencer, A.; Attal, M.; Prince, H.M.; Harousseau, J.L.; Dmoszynska, A.; San Miguel, J.; Hellmann, A.; Facon, T.; Foà, R.; Corso, A.; Masliak, Z.; Olesnyckyj, M.; Yu, Z.; Patin, J.; Zeldis, J.B.; Knight, R.D.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med., 2007, 357(21), 2123-2132.
34. Weber, D.M., Chen, C.; Niesvizky, R.; Wang, M.; Belch, A.; Stadtmauer, E.A.; Siegel, D.; Borrello, I.; Rajkumar, S.V.; Chanan-Khan, A.A.; Lonial, S.; Yu, Z.; Patin, J.; Olesnyckyj, M.; Zeldis, J.B.; Knight, R.D. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Eng l. J. Med., 2007, 357(21), 2133-2142.
35. Rajkumar, S.V.; Jacobus, S.; Callander, N.S.; Fonseca, R.; Vesole, D.H.; Williams, M.E.; Abonour, R.; Siegel, D.S.; Katz, M.; Greipp, P.R.; Eastern Cooperative Oncology Group., Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol., 2010, 11(1), 29-37.
36. Richardson, P.G.; Weller, E.; Lonial, S.; Jakubowiak, A.J.; Jagannath, S.; Raje, N.S.; Avigan, D.E.; Xie, W.; Ghobrial, I.M.; Schlossman, R.L.; Mazumder, A.; Munshi, N.C.; Vesole, D.H.; Joyce, R.; Kaufman, J.L.; Doss, D.; Warren, D.L.; Lunde, L.E.; Kaster, S.; Delaney, C.; Hideshima, T.; Mitsiades, C.S.; Knight, R.; Esseltine, D.L.; Anderson, K.C. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116(5), 679-686.
37. Kumar, S.K., et al., Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia, 2010, 24(7),1350-6.
38. McCarthy, P.L.M.; Owzar, K.; Anderson, K.C.; Craig, C.; Hofmeister, M.D.; Hurd D.D.; Hassoun, H.; Giralt, S.; Stadtmauer, E.A.; Richardson, P.G.; Weisdorf, D.J.; Vij, R.; Jan, S.; Moreb, Natalie Scott Callander, Van Besien, K.; Gentile, T.; Isola, L.; Maziarz, R.T.; Gabriel, D.A.; Bashey, A.; Landau, H.; Martin, T.; Qazilbash, M.H.; Levitan, D.; McClune, B.; Hars, V.; Postiglione, J.; Jiang C.; Bennett, E.; Barry, S.S.; Bressler, L.; Kelly, M.; Sexton, M.; Rosenbaum, C.; Parameswaran, H.; Pasquini, M.C.; Horowitz, M.M.; Shea, T.C.; Devine, S.M.; Linker, C. Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. in ASH Annual Meeting. 2010.
39. Michel Attal, M.; Lauwers, V.C.; Marit, G.; Caillot, D.; Facon, T.; Hulin, C.; Moreau, P.; Mathiot, C.; Roussel, Payen M.C.; Avet-Loiseau, H.; Harousseau J.C. Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02. in ASH Annual Meeting 2010.
40. Anderson, G.; Gries, M.; Kurihara, N.; Honjo, T.; Anderson, J.; Donnenberg, V.; Donnenberg, A.; Ghobrial, I.; Mapara, M.Y.; Stirling, D.; Roodman, D.; Lentzsch, S. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood, 2006, 107(8), 3098-30105.
41. Richardson, P.; Baz, R.; Kelley, S.L.; Munshi, N.C.; Sullivan, D.; McBride, L.; Doss, D.; Larkins, G.; Jacques, C.; Donaldson, A.; Anderson, KC. A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib in ASH Annual Meeting 2009.
42. Lacy, M.Q.; Hayman, S.R.; Gertz, M.A.; Dispenzieri, A.; Buadi, F.; Kumar, S.; Greipp, P.R.; Lust, J.A.; Russell, S.J.; Dingli, D.; Kyle, R.A.; Fonseca, R.; Bergsagel, P.L.; Roy, V.; Mikhael, J.R.; Stewart, A.K.; Laumann, K.; Allred, J.B.; Mandrekar, S.J.; Rajkumar, S.V. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol., 2009, 27(30), 5008-5014.
43. Ocio, E.M.; Mateos, M.V.; Maiso, P.; Pandiella, A.; San-Miguel, J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol., 2008, 9(12), 1157-1165.
44. Mitsiades, N.; Mitsiades, C.S.; Richardson, P.G.; McMullan, C.; Poulaki, V.; Fanourakis, G.; Schlossman, R.; Chauhan, D.; Munshi, N.C.; Hideshima, T.; Richon, V.M.; Marks, P.A.; Anderson, K.C. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 2003, 101(10), 4055-4062.
45. Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res., 2007, 5(10), 981-9.
46. Olsen, E.A.; Kim, Y.H.; Kuzel, T.M.; Pacheco, T.R.; Foss, F.M.; Parker, S.; Frankel, S.R.; Chen, C.; Ricker, J.L.; Arduino, J.M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol., 2007, 25(21), 3109-3115.
47. Mitsiades, C.S.; Mitsiades, N.S.; McMullan, C.J.; Poulaki, V.; Shringarpure, R.; Hideshima, T.; Akiyama, M.; Chauhan, D.; Munshi, N.; Gu, X.; Bailey, C.; Joseph, M.; Libermann, T.A.; Richon, V.M.; Marks, P.A.; Anderson, K.C. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl. Acad. Sci. USA, 2004, 101(2), 540-5.
48. Richardson, P.; Mitsiades, C.; Colson, K.; Reilly, E.; McBride, L.; Chiao, J.; Sun, L.; Ricker, J.; Rizvi, S.; Oerth, C.; Atkins, B.; Fearen, I.; Anderson, K.; Siegel, D. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk. Lymphoma, 2008, 49(3), 502-7.
49. Chanan-Khan, A.A.; Borrello, I.; Lee, K.P.; Reece, D.E. Development of target-specific treatments in multiple myeloma. Br. J. Haematol., 2010, 151(1), 3-15.
50. Badros, A.; Burger, A.M.; Philip, S.; Niesvizky, R.; Kolla, S.S.; Goloubeva, O.; Harris, C.; Zwiebel, J.; Wright, J.J.; Espinoza-Delgado, I.; Baer, M.R.; Holleran, J.L.; Egorin, M.J.; Grant, S. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin. Cancer Res., 2009, 15(16), 5250-7.
51. San-Miguel, J.F.; D. S. Siegel, A. Guenther, J. Blade, I. W. Prosser, B. Bengoudifa, M. Klebsattel, P. M. Bourquelot, K. C. Anderson. Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). in ASCO Annual Meeting. 2010.
52. Alsina, M.; D. M. Weber, S. E. Coutre, B. P. Kang, T. Glynos, G. Warsi, S. M. Snodgrass, P. G. Richardson; H. Lee PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). in ASCO Annual Meeting. 2010.
53. Mateos, M.; A.S. K. Taylor, S. Lonial, J. De La Rubia, T. Facon, B. Bengoudifa, K. Hazell, P. M. Bourquelot, J. F. San-Miguel. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). in ASCO Annual Meeting. 2010.
54. Massimo Offidani, M., Federica Cavallo, Claudia Polloni, Anna Marina Liberati, Stelvio Ballanti, Stefano Pulini, Massimo Catarini, Francesco Alesiani, Laura Corvatta, Silvia Gentili, Mario Boccadoro, Pietro Leoni, MD and Antonio Palumbo. Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study in ASH Annual Meeting. 2010.
55. Kawauchi, K.; Ogasawara, T.; Yasuyama, M.; Otsuka, K.; Yamada, O. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med. Chem., 2009, 9(5), 550-9.
56. Hideshima, T.; Catley, L.; Yasui, H.; Ishitsuka, K.; Raje, N.; Mitsiades, C.; Podar, K.; Munshi, N.C.; Chauhan, D.; Richardson, P.G.; Anderson, K.C. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107(10), 4053-4062.
57. Richardson, P.G.; Wolf, J.; Jakubowiak, A.; Zonder, J.; Lonial, S.; Irwin, D.; Densmore, J.; Krishnan, A.; Raje, N.; Bar, M.; Martin, T.; Schlossman, R.; Ghobrial, I.M.; Munshi, N.; Laubach, J.; Allerton, J.; Hideshima, T.; Colson, K.; Poradosu, E.; Gardner, L.; Sportelli, P.; Anderson, K.C. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J. Clin. Oncol., 2011, 29(32), 4243-9.
58. Dowling, R.J.; Topisirovic, I.; Fonseca, B.D.; Sonenberg, N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim. Biophys. Acta, 2010, 1804(3), 433-9.
59. Peterson, T.R.; Laplante, M.; Thoreen, C.C.; Sancak, Y.; Kang, S.A.; Kuehl, W.M.; Gray, N.S.; Sabatini, D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell, 2009, 137(5), 873-886.
60. Farag, S.S.; Zhang, S.; Jansak, B.S.; Wang, X.; Kraut, E.; Chan, K.; Dancey, J.E.; Grever, M.R. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk. Res., 2009, 33(11),1475-1480.
61. Ghobrial, I.M.; Weller, E.; Vij, R.; Munshi, N.C.; Banwait, R.; Bagshaw, M.; Schlossman, R.; Leduc, R.; Chuma, S.; Kunsman, J.; Laubach, J.; Jakubowiak, A.J.; Maiso, P.; Roccaro, A.; Armand, P.; Dollard, A.; Warren, D.; Harris, B.; Poon, T.; Sam, A.; Rodig, S.; Anderson, K.C.; Richardson, P.G. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol., 2011, 12(3), 263-272.
62. Guenther, A.; Burger, B. P.; Klapper, R. W.; Schmidmaier, R.; Gramatzki M. Single-agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study. in ASCO Annual Meeting. 2010. Chicago.
63. Mahindra A.K., R.P.G. Hari., Laubach J., Ghobrial I.M., Schlossman R.L., Weller E., N. C. Munshi, K. C. Anderson, Raje N.S. Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma. in ASCO Annual Meeting. 2010. Chicago.
64. Choo, A.Y.; Yoon, S.O.; Kim, S.G.; Roux, P.P.; Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA, 2008, 105(45), 17414-17419.
65. Huang, J.; Manning, B.D. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans, 2009. 37(Pt 1): p. 217-222.
66. O'Reilly, K.E., Rojo, F.; She, Q.B.; Solit, D.; Mills, G.B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D.J.; Ludwig, D.L.; Baselga, J.; Rosen, N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res., 2006, 66(3), 1500-1508.
67. Cirstea, D., et al., Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther, 2010. 9(4): p. 963-975.
68. Baumann, P.; Hagemeier, H.; Mandl-Weber, S.; Franke, D.; Schmidmaier, R. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs, 2009, 20(4), 259-266.
69. Whitesell, L.; Lindquist, S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer, 2005, 5(10), 761-772.
70. Davenport, E.L.; Moore, H.E.; Dunlop, A.S.; Sharp, S.Y.; Workman, P.; Morgan, G.J.; Davies, F.E. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood, 2007, 110(7), 2641-9.
71. Mitsiades, C.S.; Hideshima, T.; Chauhan, D.; McMillin, D.W.; Klippel, S.; Laubach, J.P.; Munshi, N.C.; Anderson, K.C.; Richardson, P.G. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin. Hematol., 2009, 46(2), 166-175.
72. Richardson, P.G.; S. Lonial, A. Krishnan, M. Carroll, M. Alsina, M. Albitar, D. Berman, S. Kaplita, K. Anderson. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. in ASCO Annual Meeting. 2009.
73. Hoang, B.; Benavides, A.; Shi, Y.; Frost, P.; Lichtenstein, A. Effect of autophagy on multiple myeloma cell viability. Mol. Cancer Ther., 2009, 8(7), 1974-1984.
74. Michallet, A.S.; Mondiere, P.; Taillardet, M.; Leverrier, Y.; Genestier, L.; Defrance, T. Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS One, 2011, 6(10), e25820.
75. Yanamandra, N.; Colaco, N.M.; Parquet, N.A.; Buzzeo, R.W.; Boulware, D.; Wright, G.; Perez, L.E, Dalton WS, Beaupre DM. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin. Cancer Res., 2006, 12(2), 591-599.
76. Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K.C. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene, 2007, 26(16), 2374-2380.
77. Gorgun, G.; Calabrese, E.; Hideshima, T.; Ecsedy, J.; Perrone, G.; Mani, M.; Ikeda, H.; Bianchi, G.; Hu, Y.; Cirstea, D.; Santo, L.; Tai, Y.T.; Nahar, S.; Zheng, M.; Bandi, M.; Carrasco, R.D.; Raje, N.; Munshi, N.; Richardson, P.; Anderson, K.C. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood, 2010, 115(25), 5202-5213.
78. Santo, L.; Hideshima, T.; Cirstea, D.; Bandi, M.; Nelson, E.A.; Gorgun, G.; Rodig, S.; Vallet, S.; Pozzi, S.; Patel, K.; Unitt, C.; Squires, M.; Hu, Y.; Chauhan, D.; Mahindra, A.; Munshi, N.C.; Anderson, K.C.; Raje, N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin. Cancer Res., 2011, 17(10), 3259-3271.
79. Siegel, D.S., Krishnan, A., Lonial, S., Chatta, G., Alsina, M., Jagannath, S., Richardson, P., Hohl, R.J., Lust, J.A., Bensinger, W., Carrum, G., Moreb, J., Simic, A., Barlogie, B., Maziarz, R.T., Anderson, K.C., Lin, J., Lowe, A., Vetticaden, S. & Zhu, J. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). in ASH Annual Meeting. 2006.
80. Shah JJ, Zonder JA, Cohen A, Weber D, Thomas S, Wang M, Kaufman JL, Burt SM, Walker D, Freeman B, Selena Armistead Rush, BS, Ann Ptaszynski, Robert Z. Orlowski and Lonial S. A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. in ASH Annual Meeting. 2010.
81. Mateos, M.V.; Cibeira, M.T.; Richardson, P.G.; Prosper, F.; Oriol, A.; de la Rubia, J.; Lahuerta, J.J.; García-Sanz, R.; Extremera, S.; Szyldergemajn, S.; Corrado, C.; Singer, H.; Mitsiades, C.S.; Anderson, K.C.; Bladé, J.; San Miguel, J. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin. Cancer Res., 2010, 16(12), 3260-9.
82. Podar, K.; Raab, M.S.; Zhang, J.; McMillin, D.; Breitkreutz, I.; Tai, Y.T.; Lin, B.K.; Munshi, N.; Hideshima, T.; Chauhan, D.; Anderson, K.C. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood, 2007, 109(4), 1669-1677.
83. Tai, Y.T.; Fulciniti, M.; Hideshima, T.; Song, W.; Leiba, M.; Li, X.F.; Rumizen, M.; Burger, P.; Morrison, A.; Podar, K.; Chauhan, D.; Tassone, P.; Richardson, P.; Munshi, N.C.; Ghobrial, I.M.; Anderson, K.C.Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood, 2007, 110(5), 1656-1663.
84. Pierre, F.; Chua, P.C.; O'Brien, S.E.; Siddiqui-Jain, A.; Bourbon, P.; Haddach, M.; Michaux, J.; Nagasawa, J.; Schwaebe, M.K.; Stefan, E.; Vialettes, A.; Whitten, J.P.; Chen, T.K.; Darjania, L.; Stansfield, R.; Bliesath, J.; Drygin, D.; Ho, C.; Omori, M.; Proffitt, C.; Streiner, N.; Rice, W.G.; Ryckman, D.M.; Anderes, K. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Mol. Cell Biochem, 2011, 356(1-2), 37-43.
85. Shammas, M.A.; Koley, H.; Bertheau, R.C.; Neri, P.; Fulciniti, M.; Tassone, P.; Blotta, S.; Protopopov, A.; Mitsiades, C.; Batchu, R.B.; Anderson, K.C.; Chin, A.; Gryaznov, S.; Munshi, N.C. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia, 2008, 22(7), 1410-1418.
86. Shishodia, S.; Sethi, G.; Konopleva, M.; Andreeff, M.; Aggarwal, B.B. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemo-therapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin. Cancer Res., 2006, 12(6), 1828-1838.
87. Mendelsohn, J.; Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol., 2006, 33(4), 369-385.
88. Mahtouk, K.; Hose, D.; Rème, T.; De Vos, J.; Jourdan, M.; Moreaux, J.; Fiol, G.; Raab, M.; Jourdan, E.; Grau, V.; Moos, M.; Goldschmidt, H.; Baudard, M.; Rossi, J.F.; Cremer, F.W.; Klein, B. Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene, 2005, 24(21), 3512-3524.
89. Mahtouk, K., Jourdan, M.; De Vos, J.; Hertogh, C.; Fiol, G.; Jourdan, E.; Rossi, J.F.; Klein, B. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood, 2004, 103(5), 1829-1837.
90. Boll, B.; Eichenauer, D.A.; Vo n Tresckow, B.; Peine, D.; Hallek, M.; Engert, A.; Hübel, K. Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. Leuk. Lymphoma, 2010, 51(3), 562-564.
91. Voorhees, P.M.; Chen, Q.; Kuhn, D.J.; Small, G.W.; Hunsucker, S.A.; Strader, J.S.; Corringham, R.E.; Zaki, M.H.; Nemeth, J.A.; Orlowski, R.Z. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res., 2007, 13(21), 6469-6478.
92. Voorhees, P.M.; Somlo, G.; Lentzsch, S.; Jagannath, S.; Sonneveld, P.; Frank, R.C.; Zweegman, S.; Wijermans, P.W.; Thomas, S. A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM). J. Clin. Oncol., 2009, 27(15s).
93. Rossi, J.F.; Manges, R.F.; Sutherland, H.J.; Jagannath, S.; Voorhees, P.M.; Sonneveld, P.; Delforge, M.; Pegourie, B.; Alegre, A.; Javier de la Rubia, La Police, D.; Bandekar B.S.; Xie, H.; Orlowski, R.Z. Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma 2008.
94. Yoshio-Hoshino, N.; Adachi, Y.; Aoki, C.; Pereboev, A.; Curiel, D.T.; Nishimoto, N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res., 2007, 67(3), 871-875.
95. Hsi, E.D.; Steinle, R.; Balasa, B.; Szmania, S.; Draksharapu, A.; Shum, B.P.; Huseni, M.; Powers, D.; Nanisetti, A.; Zhang, Y.; Rice, A.G.; van Abbema, A.; Wong, M.; Liu, G.; Zhan, F.; Dillon, M.; Chen, S.; Rhodes, S.; Fuh, F.; Tsurushita, N.; Kumar, S.; Vexler, V.; Shaughnessy, J.D. Jr.; Barlogie, B.; van Rhee, F.; Hussein, M.; Afar, D.E.; Williams, M.B. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res., 2008, 14(9), 2775-2784.
96. Tai, Y.T.; Dillon, M.; Song, W.; Leiba, M.; Li, X.F.; Burger, P.; Lee, A.I.; Podar, K.; Hideshima, T.; Rice, A.G.; van Abbema, A.; Jesaitis, L.; Caras, I.; Law, D.; Weller, E.; Xie, W.; Richardson, P.; Munshi, N.C.; Mathiot, C.; Avet-Loiseau, H.; Afar, D.E.; Anderson, K.C. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 2008, 112(4), 1329-1337.
97. Lonial S. R.V., J. Harousseau, T. Facon, P. Moreau, X. Leleu, C. Westland, A. K. Singhal, Jagannath S., Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study., in ASCO Annual Meeting. 2010.
98. Jakubowiak, A.J.; Bensinger, W.; Siegel, D.S.; Zimmerman, T.M.; Mohrbacher, A.; Richardson, P.G.; Afar, D.; Singhal, A.K.; Anderson K.C. Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study. in ASCO. 2010.
99. Westendorf, J.J., et al., Molecular and biological role of CD40 in multiple myeloma. Curr. To p. Microbiol. Immunol., 1995, 194, 63-72.
100. Tai, Y.T.; Catley, L.P.; Mitsiades, C.S.; Burger, R.; Podar, K.; Shringpaure, R.; Hideshima, T.; Chauhan, D.; Hamasaki, M.; Ishitsuka, K.; Richardson, P.; Treon, S.P.; Munshi, N.C.; Anderson, K.C. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res.; 2004, 64(8), 2846-2852.
101. Hayashi, T.; Treon, S.P.; Hideshima, T.; Tai, Y.T.; Akiyama, M.; Richardson, P.; Chauhan, D.; Grewal, I.S.; Anderson, K.C. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br. J. Haematol., 2003, 121(4), 592-596.
102. Lutz, R.J.; Whiteman, K.R. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs, 2009, 1(6), 548-551.
103. Benson, D.M. Jr.; Bakan, C.E.; Mishra, A.; Hofmeister, C.C.; Efebera, Y.; Becknell, B.; Baiocchi, R.A.; Zhang, J.; Yu, J.; Smith, M.K.; Greenfield, C.N.; Porcu, P.; Devine, S.M.; Rotem-Yehudar, R.; Lozanski, G.; Byrd, J.C.; Caligiuri, M.A. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood, 2010, 116(13), 2286-2294.
104. Coluccia, A.M.; Cirulli, T.; Neri, P.; Mangieri, D.; Colanardi, M.C.; Gnoni, A.; Di Renzo, N.; Dammacco, F.; Tassone, P.; Ribatti, D.; Gambacorti-Passerini, C.; Vacca, A. Validation of PDGFRbeta and c-Src tyrosin e kinases as tumor/vesse l ta rg ets in p a tien ts with m u ltip le myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood, 2008, 112(4), 1346-1356.
105. Shah, N.; Shpall, E.J. NK antibody therapy: KIR-ative intent. Blood, 2009, 114(13), 2567-8.
106. Fulciniti, M.; Tassone, P.; Hideshima, T.; Vallet, S.; Nanjappa, P.; Ettenberg, S.A.; Shen, Z.; Patel, N.; Tai, Y.T.; Chauhan, D.; Mitsiades, C.; Prabhala, R.; Raje, N.; Anderson, K.C.; Stover, D.R.; Munshi, N.C. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 2009, 114(2), 371-379.
107. Ishii, T.; Chanan-Khan, A.; Jafferjee, J.; Ersing, N.; Takahashi, H.; Mizutani, M.; Shiotsu, Y.; Hanai, N. A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti-Tumor Activity in Mouse Xenograft Models in ASH Annual Meeting. 2008.
108. de Weers, M.; Tai, Y.T.; van der Veer, M.S.; Bakker, J.M.; Vink, T.; Jacobs, D.C.; Oomen, L.A.; Peipp, M.; Valerius, T.; Slootstra, J.W.; Mutis, T.; Bleeker, W.; Anderson, K.; Lokhorst, H.M.; van de Winkel, J.G.; Parren, P.W. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol., 2011, 186(3), 1840-1848.
109. Kovjazin, R.; Volovitz, I.; Kundel, Y.; Rosenbaum, E.; Medalia, G.; Horn, G.; Smorodinsky, N.I.; Brenner, B.; Carmon, L. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine, 2011, 29(29-30), 4676-4686.
110. Kaufman, J.L.; E.A Stadtmauer,; A Chanan-Khan,; D Siegel,; H Horne,; N Teoh,; W.A Wegener,; Goldenberg D.M.; Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma. in ASCO Annual Meeting. 2009.
111. Nagler, A.; Shimoni, A.; Avivi, I.; Rowe J.M.; Beider, K.; Hardan, I.; Abraham, M.; Wald, H.; Galun, E.; Shaw, H.L.; Eizenberg, O.; Peled A. BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation in ASH Annual Meeting. 2010.
112. Azab, A.K.; Runnels, J.M.; Pitsillides, C.; Moreau, A.S.; Azab, F.; Leleu, X.; Jia, X.; Wright, R.; Ospina, B.; Carlson, A.L.; Alt, C.; Burwick, N.; Roccaro, A.M.; Ngo, H.T.; Farag, M.; Melhem, M.R.; Sacco, A.; Munshi, N.C.; Hideshima, T.; Rollins, B.J.; Anderson, K.C.; Kung, A.L.; Lin, C.P.; Ghobrial, I.M. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 2009, 113(18), 4341-4351.
113. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Lutz, R.J.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Vallet, S.; Pozzi, S.; Santo, L.; Perrone, G.; Tai, Y.T.; Cirstea, D.; Raje, N.S.; Uherek, C.; Dälken, B.; Aigner, S.; Osterroth, F.; Munshi, N.; Richardson, P.; Anderson, K.C. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res., 2009, 15(12), 4028-40237.